Abstract
Autologous stem cell transplantation (ASCT) has become the standard of care for eligible patients with newly diagnosed multiple myeloma (MM). Although, attaining best pre-transplant response is important for long-term disease control, early progressive disease after ASCT is not fully understood in a subset of MM patients. The aim of this study is was to evaluate risk factors and clinical features of patients with early progression of disease after ASCT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
